Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
02 06 2020
Historique:
pubmed: 20 5 2020
medline: 11 3 2021
entrez: 20 5 2020
Statut: ppublish

Résumé

Background Neprilysin is a transmembrane endopeptidase involved in the breakdown of a variety of vasoactive peptides and serves as a therapeutic target in heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate the relationship of circulating neprilysin with neurohumoral activation and the impact of plasma neprilysin activity on prognosis in HFrEF. Methods and Results A total of 369 chronic HFrEF patients were enrolled prospectively. Plasma neprilysin concentration and activity were determined by a specific ELISA and a fluorometric method. The association between plasma neprilysin and heart failure (HF) severity, neurohumoral activation, ie norepinephrine and absolute renin concentration, as well as all-cause mortality was assessed. Median plasma neprilysin concentrations and activity levels were 413 pg/mL (interquartile range 0-4111) and 2.36 nmol/mL per minute (interquartile range 1.16-4.59). No correlation could be shown between plasma neprilysin concentrations and activity (

Identifiants

pubmed: 32427034
doi: 10.1161/JAHA.119.015071
pmc: PMC7428996
doi:

Substances chimiques

Biomarkers 0
Cardiovascular Agents 0
Neurotransmitter Agents 0
Peptide Fragments 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptide, Brain 114471-18-0
Renin EC 3.4.23.15
Neprilysin EC 3.4.24.11
Norepinephrine X4W3ENH1CV

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e015071

Références

J Hepatol. 2005 Nov;43(5):791-8
pubmed: 16085334
Circulation. 1992 Feb;85(2):790-804
pubmed: 1370925
J Mol Biol. 2000 Feb 18;296(2):341-9
pubmed: 10669592
J Hypertens. 1993 Apr;11(4):407-16
pubmed: 8390508
J Clin Invest. 1983 Aug;72(2):732-8
pubmed: 6135712
J Heart Lung Transplant. 2016 May;35(5):684-5
pubmed: 26830756
JACC Heart Fail. 2015 Aug;3(8):629-36
pubmed: 26251090
J Am Heart Assoc. 2019 Aug 6;8(15):e012943
pubmed: 31345101
Eur J Heart Fail. 2019 May;21(5):598-605
pubmed: 30520545
Am J Physiol Renal Physiol. 2006 Jun;290(6):F1337-43
pubmed: 16449355
Lab Invest. 1988 Feb;58(2):210-7
pubmed: 3276960
Biochem J. 1973 May;134(1):43-57
pubmed: 4146672
J Am Coll Cardiol. 2015 Feb 24;65(7):657-65
pubmed: 25677426
Leukemia. 2001 Mar;15(3):406-14
pubmed: 11237064
Sci Rep. 2013;3:1197
pubmed: 23378928
FASEB J. 1989 Feb;3(2):145-51
pubmed: 2521610
Clin Lab. 2002;48(1-2):61-71
pubmed: 11833678
PLoS One. 2010 Sep 16;5(9):
pubmed: 20862277
J Am Heart Assoc. 2020 Jun 2;9(11):e015071
pubmed: 32427034
JACC Heart Fail. 2020 Jan;8(1):70-80
pubmed: 31392960
Sci Rep. 2019 Feb 22;9(1):2554
pubmed: 30796257
Eur J Heart Fail. 2016 Jan;18(1):89-93
pubmed: 26725876
J Am Coll Cardiol. 2016 Aug 9;68(6):639-653
pubmed: 27491909
Circulation. 1988 Apr;77(4):721-30
pubmed: 3280156
Cell Mol Life Sci. 1999 Dec;56(11-12):1008-19
pubmed: 11212319
Br J Anaesth. 1981 Jul;53(7):711-8
pubmed: 7018541
Nephrol Dial Transplant. 2019 Jan 1;34(1):100-108
pubmed: 29635392
J Am Heart Assoc. 2017 Aug 18;6(8):
pubmed: 28862951
Science. 2001 May 25;292(5521):1550-2
pubmed: 11375493
Nat Med. 1998 Jan;4(1):50-7
pubmed: 9427606
Ann N Y Acad Sci. 1996 Mar 22;780:156-63
pubmed: 8602728
Mayo Clin Proc. 2009 Sep;84(9):822-30
pubmed: 19720780
Methods Find Exp Clin Pharmacol. 2000 Dec;22(10):709-23
pubmed: 11346891
Biomed Res Int. 2018 Jul 26;2018:7279036
pubmed: 30148170
J Hum Hypertens. 2007 Jan;21(1):20-7
pubmed: 17096009
Kidney Int. 1995 Mar;47(3):855-60
pubmed: 7752584
Stem Cells. 2011 Mar;29(3):389-96
pubmed: 21425402
Rev Neurol (Paris). 2016 Dec;172(12):775-778
pubmed: 27866730
Biochem Biophys Res Commun. 2014 Apr 4;446(2):423-7
pubmed: 24495806
Rev Esp Cardiol (Engl Ed). 2015 Dec;68(12):1075-84
pubmed: 26297179
J Clin Invest. 1994 Feb;93(2):684-91
pubmed: 8113403
Am J Pathol. 2009 Mar;174(3):782-96
pubmed: 19234135
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Eur Heart J. 2004 Feb;25(4):292-9
pubmed: 14984917
Biochem Pharmacol. 1990 Apr 15;39(8):1353-6
pubmed: 2322317
Clin Chem. 1992 Sep;38(9):1785-91
pubmed: 1526015
Clin Chem. 2018 Mar;64(3):597-608
pubmed: 29138270

Auteurs

Suriya Prausmüller (S)

Department of Internal Medicine II Division of Cardiology Medical University of Vienna Vienna Austria.

Henrike Arfsten (H)

Department of Internal Medicine II Division of Cardiology Medical University of Vienna Vienna Austria.

Georg Spinka (G)

Department of Internal Medicine II Division of Cardiology Medical University of Vienna Vienna Austria.

Claudia Freitag (C)

Department of Internal Medicine II Division of Cardiology Medical University of Vienna Vienna Austria.

Philipp E Bartko (PE)

Department of Internal Medicine II Division of Cardiology Medical University of Vienna Vienna Austria.

Georg Goliasch (G)

Department of Internal Medicine II Division of Cardiology Medical University of Vienna Vienna Austria.

Guido Strunk (G)

Complexity Research Vienna Austria.

Noemi Pavo (N)

Department of Internal Medicine II Division of Cardiology Medical University of Vienna Vienna Austria.

Martin Hülsmann (M)

Department of Internal Medicine II Division of Cardiology Medical University of Vienna Vienna Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH